BGTBIO-GENE TECHNOLOGY LTD
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 10 Aug 2026, 23:49 | Notification regarding unquoted securities - BGT | Other | — | 06021 | |
| 10 Aug 2026, 23:33 | Change of Director's Interest Notice x 4 | Director Interests | — | 02009 | |
| 10 Aug 2026, 23:30 | Placement Completed and Cleansing Notice | Capital Raising | — | 06003, 06017, 06018 | |
| 10 Aug 2026, 23:02 | Application for quotation of securities - BGT | Other | — | 06020 | |
| 10 Aug 2026, 22:57 | Application for quotation of securities - BGT | Other | — | 06020 | |
| 10 Aug 2026, 22:56 | Application for quotation of securities - BGT | Other | — | 06020 | |
| 5 Aug 2026, 23:03 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 31 July 2026, 21:25 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 7 July 2026, 00:38 | Notice of Extraordinary General Meeting/Proxy Form | Meetings & Governance | — | 08002, 08004, 16002 | |
| 24 June 2026, 18:23 | Result of Security Purchase Plan | Capital Raising | — | 06017 | |
| 24 June 2026, 18:22 | Application for quotation of securities - BGT | Other | — | 06020 | |
| 5 June 2026, 18:59 | Update - Proposed issue of securities - BGT | Securities Administration | — | 06013 | |
| 3 June 2026, 19:49 | Investor Update Webinar | Presentations | — | 14014 | |
| 3 June 2026, 01:18 | Launch of Security Purchase Plan | Capital Raising | — | 06017 | |
| 2 June 2026, 19:48 | Placement Update and Section 708A(5)(e) Notice | Capital Raising | — | 06003, 06018 | |
| 2 June 2026, 19:40 | Application for quotation of securities - BGT | Other | — | 06020 | |
| 2 June 2026, 19:33 | Proposed issue of securities - BGT | Securities Administration | — | 06013 | |
| 26 May 2026, 20:01 | Proposed issue of securities - BGT | Securities Administration | — | 06013 | |
| 26 May 2026, 20:01 | Proposed issue of securities - BGT | Securities Administration | — | 06013 | |
| 26 May 2026, 20:01 | Investor Presentation - Placement | Presentations | — | 03026 | |
| 26 May 2026, 19:59 | Results of Placement | Capital Raising | MS | 06003, 06017, 09014 | |
| 22 May 2026, 19:28 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 21 May 2026, 18:34 | BGT to expand Flavocide and Qcide evaluation to Asia | Company Update | — | 11001 | |
| 6 May 2026, 19:49 | Key insecticide combinations patent allowed in the US | Company Update | — | 11001 | |
| 27 Apr 2026, 21:55 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 | |
| 20 Apr 2026, 19:32 | Investor Presentation | Presentations | — | 03026, 12008 | |
| 14 Apr 2026, 19:33 | Change of Auditor | Other | — | 12018 | |
| 26 Mar 2026, 23:20 | NWR Healthcare Conference Presentation | Presentations | — | 03026 | |
| 20 Mar 2026, 20:58 | Bio-Gene to present at NWR Healthcare Conference | Presentations | — | 14014 | |
| 16 Mar 2026, 19:18 | Sumitomo & Nakashima to launch Qcide products in Japan | Company Update | MS | 11001 | |
| 10 Mar 2026, 20:28 | Update on Qcide Production | Company Update | — | 11001 | |
| 3 Mar 2026, 20:05 | Regulatory Development of Flavocide | Company Update | MS | 11001 | |
| 24 Feb 2026, 20:35 | Appendix 4D and Half-Year Accounts 31 December 2025 | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 13 Feb 2026, 20:45 | Flavocide Acute Neurotoxicity Study Underway | Company Update | — | 11001 | |
| 9 Feb 2026, 20:31 | Flavocide Reproductive Toxicity Study Underway | Company Update | — | 11001 | |
| 2 Feb 2026, 20:11 | CFO and Company Secretary Appointment/Resignation | Company Administration | — | 12007, 12008 | |
| 30 Jan 2026, 19:24 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002, 19007 | |
| 18 Dec 2025, 19:53 | U.S. Department of Defense Grant Programs Advance | Company Update | MS | 11001 | |
| 2 Dec 2025, 19:21 | Outcome of review of Continuous Disclosure Procedures | Company Update | — | 11001, 12008 | |
| 25 Nov 2025, 19:16 | Bio-Gene Receives $519,500 R&D Tax Incentive | Periodic Reports | MS | 03014 | |
| 20 Nov 2025, 02:42 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 20 Nov 2025, 01:20 | CEO's Presentation | Presentations | MS | 03026, 15001 | |
| 20 Nov 2025, 01:18 | Chair's Address to Shareholders | Letters & Addresses | MS | 15002 | |
| 14 Nov 2025, 19:19 | Qcide receives organic listing status in USA | Company Update | MS | 11001 | |
| 31 Oct 2025, 19:17 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 | |
| 24 Oct 2025, 00:44 | Review of Continuous Disclosure Procedures | Company Administration | — | 12008 | |
| 18 Oct 2025, 03:54 | Notice of Annual General Meeting/Proxy Form | Presentations | — | 08001, 08004, 14014, 16002 | |
| 30 Sept 2025, 22:44 | Date of 2025 Annual General Meeting | Meetings & Governance | — | 08006, 12008 | |
| 29 Sept 2025, 23:41 | Response to ASX Aware Letter | ASX Query | MS | 17003 | |
| 23 Sept 2025, 19:29 | Positive Flavocide Efficacy Results Presented | Presentations | MS | 03026, 12008 |
1–50 of 53
1 / 2